Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 5/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16992202 | 1.00 | F2 (0.46) | F2PRSS1PRSS2PRSS3POLB | |
| SCHEMBL18314687 | 0.85 | LMNA (0.47) | F2PRSS1PRSS2PRSS3ALDH1A1 | |
| SCHEMBL5330597 | 0.85 | LMNA (0.47) | F2PRSS1PRSS2PRSS3ALDH1A1 | |
| SCHEMBL5330600 | 0.85 | LMNA (0.47) | F2PRSS1PRSS2PRSS3ALDH1A1 | |
| SCHEMBL5328711 | 0.82 | MMP13 (0.45) | F2PRSS1PRSS2PRSS3POLB | |
| SCHEMBL5375740 | 0.82 | MMP13 (0.45) | F2PRSS1PRSS2PRSS3POLB | |
| SCHEMBL5328714 | 0.82 | MMP13 (0.45) | F2PRSS1PRSS2PRSS3POLB | |
| SCHEMBL20135393 | 0.79 | ALDH1A1 (0.44) | F2PRSS1PRSS2PRSS3POLB | |
| SCHEMBL26676486 | 0.75 | ALDH1A1 (0.46) | F2PRSS1PRSS2PRSS3POLB | |
| SCHEMBL20476798 | 0.74 | ALDH1A1 (0.49) | F2PRSS1PRSS2PRSS3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| EP-3811944-A1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | Sentinel Oncology Limited (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-10973817-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3104860-B1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2020-12-30 | — | — | EP | disclosed |
| US-20180271860-A1 | PHARMACEUTICAL COMPOUNDS | CASCADIAN THERAPEUTICS, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-10010547-B2 | Pharmaceutical compounds | CASCADIAN THERAPEUTICS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| EP-3104860-A1 | PHARMACEUTICAL COMPOUNDS | Cascadian Therapeutics, Inc. (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160361310-A1 | PHARMACEUTICAL COMPOUNDS | SEATTLE GENETICS, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2015120390-A1 | PHARMACEUTICAL COMPOUNDS | ONCOTHYREON INC. (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010547-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | F2 4568/4885PRSS1 1447/4885PRSS2 2617/4885 |
| US-20180271860-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | F2 4568/4885PRSS1 1447/4885PRSS2 2617/4885 |
| US-11786524-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | F2 4568/4885PRSS1 1447/4885PRSS2 2617/4885 |
| US-20160361310-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | F2 4568/4885PRSS1 1447/4885PRSS2 2617/4885 |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | F2 4568/4885PRSS1 1447/4885PRSS2 2617/4885 |
| US-10973817-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | F2 4568/4885PRSS1 1447/4885PRSS2 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.